10th Italian Meeting on Mitochondrial Diseases
Virtual Meeting
October 9-10, 2020
Mitocon is pleased to announce the 10th Italian Meeting on Mitochondrial Diseases. Owing to the ongoing situation with Covid-19, it will be organised as a virtual conference.
The meeting will bring together doctors, researchers and patients and will be a unique opportunity to discuss and update on current understandings of mitochondrial diseases and pathways towards diagnosis and treatment.
Mitochondrial diseases are very complex disorders little known by the scientific community itself until a few years ago. In recent years, giant steps have been taken in the study of the basic mechanisms involved in these diseases and we have finally moved from the diagnosis to the study of possible treatments.
Since its first edition in 2011, the annual Italian Meeting on Mitochondrial Diseases has contributed to this process by gathering the entire community of Italian doctors and researchers around the association of patients and helping to strengthen international partnerships and collaborations, making the whole community grow together and contributing to sharing knowledge and research progress.
The program, drawn up in collaboration with Mitocon’s Scientific Committee, has been designed to inspire the integration of technology and innovation into medical practice. In addition to the natural history of diseases and pre-clinical models, we will talk about the “high tech” involvement in mitochondrial medicine, robotics and gene therapy.
A very important session will be dedicated to the research of therapies, with a specific focus on an update on current clinical trials. It will be a unique opportunity for discussion between clinicians and industry and a real possibility for new collaborations.
This 10th edition of the meeting is dedicated to one of the fathers of mitochondrial medicine, Prof. Salvatore Di Mauro, for decades leading one of the first and main research groups on mitochondria at Columbia University in NY (US), which has attracted and built entire generations of mitochondriologists in Italy and worldwide. A special lecture will be dedicated to him for his 80 years.
The meeting will be in English to facilitate participation of doctors and researchers from all over the world, promoting international exchange and collaboration, crucial to fight together against mitochondrial diseases.
On October 9 the meeting will start at 9.30 am (Italian time) and close at 7.30 pm.
On October 10 it will start at 9 am (Italian time) and close at 1.30 pm.
Main topics:
- Accelerating high tech involvement in daily practice
- Current trials and industry
- Gene therapy and editing
- Mitochondrial diseases, natural history and cohorts
- Pathophysiology and models of mitochondrial dysfunction
Scientific programme committee
Enrico Bertini, Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children’s Research Hospital, Rome
Valerio Carelli, IRCCS Institute of Neurological Sciences (ISBN), Bellaria Hospital, Bologna/University of Bologna
Massimiliano Filosto, NeMO Clinical Center-Brescia for Neuromuscolar Diseases; Department of Clinical and Experimental Sciences, University of Brescia
Costanza Lamperti, Division of Medical Genetics and Neurogenetics, Mariani Foundation Center for the Study of Mitochondrial Pediatric Diseases, Foundation IRCCS Neurological Institute “C. Besta”, Milan
Michelangelo Mancuso, AOUP, Neurological Institute, University of Pisa
Olimpia Musumeci, AOU Policlinico “G.Martino”, University of Messina
Serenella Servidei, Neurology Institute, Catholic University of the Sacred Heart, Rome
Valeria Tiranti, Division of Medical Genetics and Neurogenetics, Mariani Foundation Center for the Study of Mitochondrial Pediatric Diseases, Foundation IRCCS Neurological Institute “C. Besta”, Milan
Massimo Zeviani, Department of Neurosciences, University of Padua
Confirmed speakers
Holger Prokisch, Technical University Munich
Costanza Lamperti, Division of Medical Genetics and Neurogenetics, Mariani Foundation Center for the Study of Mitochondrial Pediatric Diseases, Foundation IRCCS Neurological Institute “C. Besta”, Milan
Daniela Zuccarello, Department of Lab Medicine, Unit of Clinical Genetics and Epidemiology, University Hospital of Padua
Anu Suomalainen, Department of Neurosciences, University of Helsinki
Matthew Klein, Global Head Gene and Mitochondrial Therapies, PTC Therapeutics
Magnus Hansson, Chief Medical Officer, Vice President Preclinical & Clinical Development, Abliva
Aidan Gill, Head of Medical EU, Minovia
Magali Taiel, MD Chief Medical Officer, GenSight Biologics
Xavier Llòria, Global Program Leader Raxone, Santhera Pharmaceuticals
Alejandro Dorenbaum, Chief Medical Officer, Reneo Pharmaceuticals
Jan Smeitink, CEO Khondrion
Carlos T. Moraes, University of Miami Miller School of Medicine
Carlo Viscomi, Department of Biomedical Sciences, University of Padua
Ramon Martí, Research group on neuromuscular and mitochondrial diseases, Vall d’Hebron Research Institute (VHIR), Barcelona
Beverly Y. Mok, Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA (USA)
Michelangelo Mancuso, AOUP, Neurological Institute, University of Pisa
Thomas Klopstock, Department of Neurology, University of Munich, Germany
Robert McFarland, Wellcome Trust Centre for Mitochondrial Research, UK
Diego Martinelli, Genetics and Rare Diseases Research Division, Unit of Metabolism, Bambino Gesù Children’s Research Hospital, Rome
Vania Broccoli, CNR – National Research Council, Institute of Neuroscience, Milan
Luca Scorrano, Department of Biology & VIMM, University of Padua
Special lecture: the mitochondrial journey. Celebrating the 80th years of Billi Di Mauro, M. Zeviani
Telemedicine during Covid-19 , C. Lamperti (online soon)
Epigenetics of pregnancy: when DNA is not the boss, D. Zuccarello
Overview of biological biomarkers, A. Suomalainen
PTC743 Mitochondrial Epilepsy Trial Update, M. Klein
Abliva’s innovative drug development programs for primary mitochondrial diseases, M. Hansson
MAT: Minovia’s journey with a Personalized Therapy, A. Gill
Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy (LHON), M. Taiel
Highlights on the state of the art of Idebenone therapy in LHON, X. Llòria
Overview of REN001 Clinical Development Program, A. Dorenbaum
Khondrion’s Sonlicromanol: progress update, J. Smeitink
Changing mtDNA heteroplasmy with DNA editing enzymes, C. T. Moraes
Experimental models for mtDNA maintenance defects, C. Viscomi
Treatment of mitochondrial diseases with AAV: the proposal of gene therapy for MNGIE, R. Martí
A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing, B. Y. Mok
Outcome measures in primary mitochondrial myopathies. M. Mancuso
Clinical course of MELAS. Can we predict it?, R. McFarland
Inflammation and mitochondrial diseases, D. Martinelli (online soon)
iPS models for OPA1 and POL Gassociated with parkinsonism, V. Broccoli
Inhibition of autophagy corrects the visual defects in a model of ADOA, L. Scorrano
MAKE A DONATION
Mitocon is an association of patients affected by mitochondrial diseases and their families striving to advance research towards a cure. Encouraging collaboration and the exchange of knowledge within the scientific community is our priority. For this reason, participation in this meeting is free, but we would be grateful if you could support our commitment and work with a donation.